Clinical Trial Detail

NCT ID NCT02007044
Title Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

prolymphocytic leukemia

CLL/SLL

Therapies

Ibrutinib

Ibrutinib + Rituximab

Age Groups: senior adult

No variant requirements are available.